Pyrimidines
Research News and Information

Sunday, November 22, 2009

Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).

13 Dec 2009 BACKGROUND: Allogeneic hematopoietic cell transplant (HCT) with best available donor for children with Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) has previously been considered standard practice. Since the introduction of ... Read more...

Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model.

29 Nov 2009 Stage 4 neuroblastoma (NB) is a devastating childhood cancer whose poor outcome has remained essentially unchanged in the last 20 years. Receptor tyrosine kinases have important roles in the control of proliferation, differentiation and apoptosis of ... Read more...

The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era.

29 Nov 2009 BACKGROUND: As the treatment of Philadelphia positive (Ph+) leukemias in the era of imatinib continues to evolve, the role of allogeneic hematopoietic cell transplantation (allogeneic-HCT) in first remission is becoming more unclear. PROCEDURE: ... Read more...

Latest indexed articles for 'Pyrimidines'

These are the very latest articles for this heading:

• Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). 13 Dec 2009
• Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model. 29 Nov 2009
• Dasatinib after allogeneic stem cell transplantation in a child with Philadelphia chromosome positive acute lymphoblastic leukemia. 29 Nov 2009
• The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. 29 Nov 2009
• Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib. 29 Nov 2009
• Kinetic mechanism and inhibitor characterization of WNK1 kinase. Nov 2009
• Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease. 30 Oct 2009
• Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro. 30 Oct 2009
• Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. 20 Oct 2009
• RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. 6 Oct 2009
• Molecular dynamics study of non-nucleoside reverse transcriptase inhibitor 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (TMC278/rilpivirine) aggregates: correlation between amphiphilic properties of the drug and oral bioavailability. 6 Oct 2009
• Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial. 4 Oct 2009
• Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. 3 Oct 2009
• Shifting paradigms: the seeds of oncogene addiction. 29 Sep 2009
• Attacking cancer at its foundation. 29 Sep 2009
• Perspectives on the development of imatinib and the future of cancer research. 29 Sep 2009
• Lasker Awards and papal portraiture: turning fields upside down. 29 Sep 2009
• Preserving fertility during cancer treatment. 29 Sep 2009
• Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. 29 Sep 2009
• The influence of hepatic impairment on the pharmacokinetics of paliperidone. 29 Sep 2009

See a longer list of these articles.

Technical information about 'Pyrimidines'

Definition: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.

Registry Number: 0

Descriptor UI: D011743

Alternative terms: Pyrimidines;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; biosynthesis;

Tree Number: D03.383.742;

Online Note: use PYRIMIDINES to search THONZYLAMINE 1972-84 (as Prov 1972)

History Note: THONZYLAMINE was heading 1972-84 (Prov 1972)